Pulse Biosciences, Inc. (PLSE) |
| 49 -0.13 (-0.26%) 08-25 16:00 |
| Open: | 49.73 |
| High: | 50.9 |
| Low: | 47.65 |
| Volume: | 366,662 |
| Market Cap: | 3,391(M) |
| PE Ratio: | -41.53 |
| Exchange: | NASDAQ Capital Market |
| Industry: | Medical - Instruments & Supplies |
| Sector: | Healthcare |
| Technical analysis | ||||
![]() |
||||
| sell | buy | |||
| Resistance 2: | 59.45 |
| Resistance 1: | 50.90 |
| Pivot price: | 44.90 |
| Support 1: | 37.68 |
| Support 2: | 29.51 |
| 52w High: | 50.9 |
| 52w Low: | 12.56 |
Pulse Biosciences, Inc. is an innovative firm specializing in bioelectric medicine. Their primary offering is the CellFX System, a sophisticated, console-based platform that is precisely controlled via software. This system utilizes its proprietary Nano-Pulse Stimulation technology to deliver extremely brief, nanosecond-duration electrical pulses. This advanced method is designed to selectively eliminate target cells without thermal damage, effectively safeguarding adjacent non-cellular tissue. The CellFX System is applied in the treatment of various medical conditions. The company, originally incorporated in 2014 as Electroblate, Inc., officially became Pulse Biosciences, Inc. in December 2015. Its corporate headquarters are situated in Hayward, California.
| EPS | -82620000.000 |
| Book Value | 0.000 |
| PEG Ratio | 0.00 |
| Gross Profit | 0.000 |
| Profit Margin (%) | 0.00 |
| Operating Margin (%) | -5.00 |
| Return on Assets (ttm) | 823.0 |
| Return on Equity (ttm) | -44.3 |
Wed, 19 Aug 2026
Pulse Biosciences (PLSE) Launched A $75 Million Offering, Is The Upside Already Priced In? - Sahm
Tue, 18 Aug 2026
Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Sun, 16 Aug 2026
Pulse Biosciences (PLSE) Is Up 5.0% After Wider Losses And $75M ATM Plan Filed – Has The Bull Case Changed? - simplywall.st
Sun, 16 Aug 2026
Pulse Biosciences (PLSE) Stock Looks Pricey On Book Value Yet Strong On Returns - Yahoo Finance
Tue, 11 Aug 2026
Pulse Biosciences, Inc. (PLSE) Stock Analysis: Exploring the Innovative Potential of a $2.96 Billion Bioelectric Medicine Leader - DirectorsTalk Interviews
Fri, 07 Aug 2026
Pulse Biosciences Q2 Earnings Call Highlights - TradingView
|
StockChart iOS |
StoxlineLite iOS |
StoxlineLite iOS |
OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |